[ 英語タイトル ] Dysmenorrhea Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089228

Survey : Mordor Intelligence

Publish On : November, 2020

Number of Pages : 105

Category : Healthcare and Pharmaceuticals

Report format : PDF

Sales price option (consumption tax not included)

[Report Description]

The dysmenorrhea treatment market is expected to register a CAGR of 8.1% during the forecast period. Dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Most of the women experience dysmenorrhea just before and during their menstrual periods. Dysmenorrhea is of two types, namely primary and secondary dysmenorrhea. Prostaglandin-induced uterine contractions cause primary dysmenorrhea and secondary dysmenorrhea means pelvic pain caused by (secondary to) a disorder or disease.

Dysmenorrhea can create complications such as endometriosis that can cause fertility problems, increasing the risk of a fertilized egg implanting outside of the uterus (ectopic pregnancy), and pelvic inflammatory disease can scar fallopian tubes.

As per the study published in the International Journal of Gynecology & Obstetrics, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most common gynecological problem worldwide.

Increasing incidence and prevalence of dysmenorrhea and growing awareness regarding dysmenorrhea among females and increasing research and development by companies for developing innovative drugs are the key driving factors in the dysmenorrhea treatment market.

Key Market Trends

Non-Steroidal Anti-Inflammatory Drugs Segment is Expected to Hold a Major Market Share in the Dysmenorrhea Treatment Market

- Some of the US Food and Drug Administration (FDA) approved NSAIDs for treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.
- According to the Women's Health Concern and British Menopause Society, about 80% of dysmenorrhea women experience period pain at some stage in their lifetime. Most women experience some discomfort during menstruation, especially on the first day. But in 5%-10% of women, the pain is severe enough to disrupt their life.
- Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also globally.
- Non-steroidal anti-inflammatory drugs segment holds a significant market share in the dysmenorrhea treatment market. It is anticipated to show a similar trend over the forecast period due to highly effective relieving pain, lower cost, and easy availability of products.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global dysmenorrhea treatment market due to the increasing incidence and prevalence of dysmenorrhea and awareness of dysmenorrhea among females in this region. As per the study published in the Indian Journal of Research, in the United States, about 2 billion dollars or 600 million working hours are lost annually because of incapacitating dysmenorrhea. Moreover, women who attend classes or work have been shown to have lower work output or scores during their dysmenorrhea. Furthermore, increasing research and development for developing innovative drugs and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The dysmenorrhea treatment market is competitive and consists of several major players. Some of the major players include Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer, Inc, GlaxoSmithKline Plc, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen, among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support